Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2022 | The safety and efficacy of fitusiran prophylaxis in patients with hemophilia A and B

Alok Srivastava • 11 Jul 2022
ISTH 2022
Hemophilia Fitusiran

Alok Srivastava, MD, FRACP, FRCPA, FRCP, Christian Medical College, Vellore, India, discusses his presentation at ISTH 2022, which focused on an analysis of two Phase III studies evaluating the safety and efficacy of fitusiran prophylaxis in patients with hemophilia A and B previously treated with bypassing agents. Results demonstrated that fitusiran prophylaxis reduced the quantity of bypassing agents and clotting factor concentrates needed, and also reduced treatment burden on patients. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.

More from Alok Srivastava

1:58
How hemophilia care has changed over the years
Alok Srivastava • 11 Jul 2022
1:48
The promise of fitusiran for the treatment of patients with hemophilia A and B
Alok Srivastava • 11 Jul 2022
1:23
The safety and efficacy of eptacog beta in patients with hemophilia
Alok Srivastava • 11 Jul 2022

Related Videos

1:08
The current landscape of hemophilia treatment: an update from ASH 2023
Glaivy Batsuli • 10 Dec 2023
1:18
Unmet needs in hemophilia treatment
Glaivy Batsuli • 10 Dec 2023
1:11
Improving outcomes for hemophilia patients through the implementation of gene therapies
Evelien Krumb • 12 Dec 2023
1:27
The impact of emicizumab on the hemophilia treatment landscape
Glaivy Batsuli • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals